{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T01:46:30Z","timestamp":1793324790127,"version":"4.5.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100010843","name":"Guangzhou Science Technology and Innovation Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010843","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010256","name":"Guangzhou Municipal Science and Technology Project","doi-asserted-by":"publisher","award":["2025A03J4290"],"award-info":[{"award-number":["2025A03J4290"]}],"id":[{"id":"10.13039\/501100010256","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010256","name":"Guangzhou Municipal Science and Technology Project","doi-asserted-by":"publisher","award":["2025A03J4292"],"award-info":[{"award-number":["2025A03J4292"]}],"id":[{"id":"10.13039\/501100010256","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.leukres.2026.108267","type":"journal-article","created":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T16:43:36Z","timestamp":1781455416000},"page":"108267","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Efficacy and safety of BCMA-directed bispecific antibodies in relapsed and\/or refractory systemic AL amyloidosis: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"167","author":[{"given":"Shuhui","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayi","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guopan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8838-7323","authenticated-orcid":false,"given":"Yangmin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2026.108267_bib1","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1002\/ajh.27177","article-title":"Immunoglobulin light chain amyloidosis: 2024 update on diagnosis, prognosis, and treatment","volume":"99","author":"Gertz","year":"2024","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.leukres.2026.108267_bib2","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1056\/NEJMoa2028631","article-title":"Daratumumab-based treatment for immunoglobulin light-chain amyloidosis","volume":"385","author":"Kastritis","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2026.108267_bib3","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1080\/13506129.2022.2093635","article-title":"Guidelines for non-transplant chemotherapy for treatment of systemic AL amyloidosis: EHA-ISA working group","volume":"30","author":"Wechalekar","year":"2023","journal-title":"Amyloid"},{"key":"10.1016\/j.leukres.2026.108267_bib4","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1038\/s41375-024-02243-5","article-title":"Treatment patterns for AL amyloidosis after frontline daratumumab, bortezomib, cyclophosphamide, and dexamethasone treatment failures","volume":"38","author":"Zanwar","year":"2024","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2026.108267_bib5","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMra2304088","article-title":"Systemic light chain amyloidosis","volume":"390","author":"Sanchorawala","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2026.108267_bib6","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41408-020-00397-w","article-title":"Venetoclax induces deep hematologic remissions in t(11;14) relapsed\/refractory AL amyloidosis","volume":"11","author":"Premkumar","year":"2021","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.leukres.2026.108267_bib7","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2026.108267_bib8","doi-asserted-by":"crossref","first-page":"3369","DOI":"10.1182\/blood-2024-199733","article-title":"Linvoseltamab in PAtients with Relapsed\/refractory Multiple Myeloma: Longer Follow-up and Selected High-risk Subgroup Analyses of the linker-MM1 study","volume":"144","author":"Shah","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2026.108267_bib9","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.leukres.2026.108267_bib10","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.leukres.2026.108267_bib11","doi-asserted-by":"crossref","first-page":"3751","DOI":"10.1200\/JCO.2004.03.029","article-title":"Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis","volume":"22","author":"Dispenzieri","year":"2004","journal-title":"JCO"},{"key":"10.1016\/j.leukres.2026.108267_bib12","doi-asserted-by":"crossref","unstructured":"Appelman Real-World Bispecific Antibody Therapy for Multiple Myeloma: Insights from Dutch Nationwide Registry. p S45.","DOI":"10.1016\/S2152-2650(25)03471-8"},{"key":"10.1016\/j.leukres.2026.108267_bib13","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/s41408-023-00950-3","article-title":"Safety and efficacy of teclistamab in systemic immunoglobulin light chain amyloidosis","volume":"13","author":"Chakraborty","year":"2023","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.leukres.2026.108267_bib14","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1182\/blood.2023022937","article-title":"Teclistamab in relapsed or refractory AL amyloidosis: a multinational retrospective case series","volume":"143","author":"Forgeard","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2026.108267_bib15","doi-asserted-by":"crossref","first-page":"5808","DOI":"10.1182\/blood-2025-5808","article-title":"A phase I\/II, open label, Study to evaluate safety, tolerability and efficacy of elranatamab in patients with relapsed or refractory AL amyloidosis: interim report of phase I results","volume":"146","author":"Hossain","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2026.108267_bib16","doi-asserted-by":"crossref","first-page":"7562","DOI":"10.1200\/JCO.2025.43.16_suppl.7562","article-title":"Teclistamab in relapsed\/refractory systemic AL amyloidosis","volume":"43","author":"Mico","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2026.108267_bib17","doi-asserted-by":"crossref","first-page":"7492","DOI":"10.1182\/blood-2025-7492","article-title":"Teclistamab induced rapid and deep hematologic response in relapsed\/refractory light chain amyloidosis: a multicenter retrospective study","volume":"146","author":"Shen","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2026.108267_bib18","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/ejh.14348","article-title":"Safety and efficacy of teclistamab in patients with relapsed or refractory al amyloidosis","volume":"114","author":"Stalker","year":"2025","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.leukres.2026.108267_bib19","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1182\/blood.2025028383","article-title":"Safety and efficacy of elranatamab in patients with relapsed and\/or refractory immunoglobulin light-chain amyloidosis","volume":"146","author":"Vianna","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2026.108267_bib20","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1200\/JCO.2011.38.5724","article-title":"Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements","volume":"30","author":"Kumar","year":"2012","journal-title":"JCO"},{"key":"10.1016\/j.leukres.2026.108267_bib21","doi-asserted-by":"crossref","first-page":"3771","DOI":"10.1182\/bloodadvances.2024015528","article-title":"Predictive value of free light chain burden in patients with AL amyloidosis treated with bortezomib-based regimens","volume":"9","author":"Saunders","year":"2025","journal-title":"Blood Adv."},{"key":"10.1016\/j.leukres.2026.108267_bib22","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1182\/blood-2023-178243","article-title":"Limited utility of mayo 2012 cardiac staging system for risk stratification of patients with advanced cardiac AL amyloidosis - analysis of a uniformly treated cohort of 1275 patients","volume":"142","author":"Khwaja","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2026.108267_bib23","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2026.108267_bib24","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.leukres.2026.108267_bib25","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1200\/JCO.2014.57.4947","article-title":"Translocation t(11;14) Is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib-based regimens","volume":"33","author":"Bochtler","year":"2015","journal-title":"JCO"},{"key":"10.1016\/j.leukres.2026.108267_bib26","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1200\/JCO-24-02252","article-title":"Efficacy and safety of anti\u2013b-cell maturation antigen chimeric antigen receptor T-cell for the treatment of relapsed and refractory AL amyloidosis","volume":"43","author":"Lebel","year":"2025","journal-title":"JCO"},{"key":"10.1016\/j.leukres.2026.108267_bib27","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1182\/bloodadvances.2025017488","article-title":"AL amyloidosis: a real-world experience with CAR T-cell therapy","volume":"10","author":"Tan","year":"2026","journal-title":"Blood Adv."},{"key":"10.1016\/j.leukres.2026.108267_bib28","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1182\/blood-2025-692","article-title":"Phase 1\/2 dose escalation and expansion study of etentamig in patients with relapsed or refractory light chain amyloidosis","volume":"146","author":"Chakraborty","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2026.108267_bib29","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/ajh.23898","article-title":"Kinetics of organ response and survival following normalization of the serum free light chain ratio in AL amyloidosis","volume":"90","author":"Kaufman","year":"2015","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.leukres.2026.108267_bib30","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1182\/blood-2025-2182","article-title":"The real-world safety and efficacy of bispecific t-cell engager therapy in systemic AL amyloidosis","volume":"146","author":"Rees","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2026.108267_bib31","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1161\/01.RES.0000126569.75419.74","article-title":"Human amyloidogenic light chains directly impair cardiomyocyte function through an increase in cellular oxidant stress","volume":"94","author":"Brenner","year":"2004","journal-title":"Circ. Res."},{"key":"10.1016\/j.leukres.2026.108267_bib32","doi-asserted-by":"crossref","first-page":"4188","DOI":"10.1073\/pnas.0912263107","article-title":"Amyloidogenic light chains induce cardiomyocyte contractile dysfunction and apoptosis via a non-canonical p38\u03b1 MAPK pathway","volume":"107","author":"Shi","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.leukres.2026.108267_bib33","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1200\/JCO.2011.37.7614","article-title":"New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes","volume":"30","author":"Palladini","year":"2012","journal-title":"JCO"},{"key":"10.1016\/j.leukres.2026.108267_bib34","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1182\/bloodadvances.2020001792","article-title":"COUNTERPOINT BiTEs better than CAR T cells","volume":"5","author":"Subklewe","year":"2021","journal-title":"Blood Adv."},{"key":"10.1016\/j.leukres.2026.108267_bib35","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1158\/2643-3230.BCD-24-0354","article-title":"Real-world experience with teclistamab for relapsed\/refractory multiple myeloma from the US Myeloma immunotherapy consortium","volume":"6","author":"Razzo","year":"2025","journal-title":"Blood Cancer Discov."},{"key":"10.1016\/j.leukres.2026.108267_bib36","doi-asserted-by":"crossref","first-page":"e205","DOI":"10.1016\/S1470-2045(24)00043-3","article-title":"International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma","volume":"25","author":"Rodriguez-Otero","year":"2024","journal-title":"Lancet Oncol."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212626001116?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212626001116?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T20:04:27Z","timestamp":1785873867000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212626001116"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":36,"alternative-id":["S0145212626001116"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2026.108267","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of BCMA-directed bispecific antibodies in relapsed and\/or refractory systemic AL amyloidosis: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2026.108267","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108267"}}